Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report

Authors

Rohail A. Baig, Arnot Ogden Medical CenterFollow
Faieja Chowdhury, OMSIV Lake Erie College of Osteopathic MedicineFollow
Omar Siddiqui, Arnot Ogden Medical CenterFollow
Adnaan Sheikh, Arnot Ogden Medical CenterFollow
Varun Mehta, Arnot Ogden Medical CenterFollow
Pranjali Dakwale, Arnot Ogden Medical CenterFollow

Author Credentials

MD

DO Student

DO

MD

MD

Author ORCID Identifier

0000-0001-9061-8936

Abstract

This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre-disposed autoimmune diseases that are on chronic pharmacotherapy.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Recommended Citation

Baig RA, Chowdhury F, Siddiqui O, Sheikh A, Mehta V, Dakwale P. Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report. Advances in Clinical Medical Research and Healthcare Delivery. 2023; 3(3). doi: 10.53785/2769-2779.1154.

Publisher Note

All articles published in ACMRHD are distributed with a Creative Commons CC BY-NC 4.0 license. Under this license, authors hold the copyright to their work and have the right to share or adapt the article with no restrictions, as long as the author(s) and source are cited, and the use is for noncommercial purposes. This policy went into effect November 1, 2023, and applies retroactively to all articles published in ACMRHD prior to that date, as well.